Contact information
Heather Halls
BSc
Researcher, Vascular Overviews Group
Heather studied Physics and Biology at King’s College, London (1979-81). She came to work as a Research Scientist at Oxford University and between 1982 and 1993 she worked on the International Study of Infarct Survival (ISIS) series of clinical trials looking at treatments for suspected heart attack.
These were some of the first very large, simple, randomised ‘mega-trials’ (ISIS-1 to ISIS-4, randomising 140,000 patients) the results of which substantially improved the emergency treatment of heart attacks.
Since 1994 her research focus has been ‘meta-analyses’ of randomised trials to determine the effects of treatments for the prevention and treatment of cardiovascular disease. These meta-analyses combine all the trials that have addressed the same treatment question and the results provide reliable evidence on their effects.
Her role has been to perform systematic searches for these trials, to procure the trial data and to develop and maintain the associated data management systems. The results of these collaborative meta-analyses have helped determine many important treatment effects including those of antiplatelets (particularly aspirin), statins and non-steroidal anti-inflammatory drugs.
Regular updates of these meta-analyses and new collaborations ensure the research continues to be relevant to patient care and evidence guidelines. It is these influences which has been the inspiration and drive for her work in medical research.
Recent publications
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group ., (2026), Lancet Infect Dis, 26, 34 - 45
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group ., (2025), Lancet Infect Dis, 25, 1000 - 1010
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Journal article
Scotland G. et al, (2025), Diabet Med, 42
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group ., (2025), EClinicalMedicine, 81

